Astorg and is to acquire CordenPharma (CordenPharma), a global pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with capabilities in active pharmaceutical ingredients, excipients, and drug products, from International Chemical Investors Group (ICIG).
As part of the transaction, the founders will take the opportunity to reinvest as partners with Astorg.
Established in 2006, CordenPharma today employs more than 2,600 people in 11 manufacturing facilities and one R&D laboratory located across Europe and the US.
Following a strategic review of its portfolio, ICIG had concluded, that CordenPharma in its next growth phase would be best developed further with a partner and that ICIG would focus more on its chemicals portfolio.
Financial terms of the transaction, which remains subject to customary regulatory approvals, have not been disclosed.
